StockNews.AI
GILD
StockNews.AI
25 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

1. Pomerantz LLP investigates Gilead for potential securities fraud. 2. FDA placed clinical hold on HIV treatment trials GS-1720 and GS-4182. 3. Gilead's stock fell 2.58% after the FDA announcement. 4. Investors can join a class action regarding Gilead's practices. 5. Safety signals in trials raised concerns about product efficacy.

3m saved
Insight
Article

FAQ

Why Bearish?

Negative news regarding FDA hold decreases investor confidence. Historical instances show that regulatory issues often lead to price declines.

How important is it?

Ongoing investigations and regulatory holds indicate significant risk for Gild's future profitability.

Why Short Term?

Immediate regulatory actions generally influence stock prices quickly. Past incidents of phase hold announcements usually see rapid market reactions.

Related Companies

BMYNVOMRNA
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Gilead and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 10, 2025, Gilead issued a press release announcing that “[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead’s HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]” specifying that “[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.”  On this news, Gilead’s stock price fell $2.91 per share, or 2.58%, to close at $110.09 per share on June 10, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News